For the first time, women experiencing genital arousal challenges have access to a clinically studied topical treatment designed specifically for their needs. Daré Bioscience is making DARE to PLAY, a sildenafil cream, available through its telehealth platform starting this summer, filling a significant gap in women's sexual health care that has gone largely unaddressed by the pharmaceutical industry.

Why Is This Treatment Different From What's Already Available?

DARE to PLAY stands out because it's the only sildenafil cream for women manufactured under FDA's current Good Manufacturing Practice (cGMP) requirements, which ensure consistent quality and potency. The formulation has been clinically studied and demonstrates increased genital blood flow within 10 to 15 minutes of application, with improvements in arousal, orgasm, and desire measured using FDA-reviewed clinical endpoints.

The need is substantial. An estimated 20 million women in the United States experience challenges related to genital arousal, yet there is currently no FDA-approved therapy that directly addresses this condition. DARE to PLAY was specifically designed to fill this void by providing women with a non-systemic option that works locally and quickly.

The product's differentiation extends beyond its formulation. Daré is pursuing a dual-path strategy: making DARE to PLAY available immediately as a Section 503B compounded product while simultaneously advancing the sildenafil cream formulation toward the traditional FDA approval pathway (505(b)(2) NDA pathway). This approach allows women access now while building toward full regulatory approval.

How Is This Product Being Made Available to Women?

• Telehealth Access: Pre-fulfillment prescribing has been available nationwide in all 50 states since February 2026 through the DARE Health Hub, Daré's telehealth platform designed to connect women efficiently to the product.
• Manufacturing Partnership: Bravado Pharmaceuticals, the 503B-registered outsourcing facility, is targeting national dispensing commencement in summer 2026 as it advances state licensing and fulfillment preparations.
• Provider-Focused Strategy: Daré is emphasizing clinician advocacy as a key driver of commercial momentum, with strong interest generated at the American College of Obstetricians and Gynecologists annual conference during the first quarter of 2026.

The commercial model is intentionally product-first rather than service-focused. The DARE Health Hub and telehealth access serve as infrastructure to connect women to the specific, clinically studied formulation, not as a subscription or services business.

What Other Women's Health Products Is This Company Launching?

Beyond DARE to PLAY, Daré Bioscience is expanding its women's health portfolio with two additional product lines expected to reach women in 2026 and 2027. Flora Sync LF5, a vaginal probiotic suppository, is anticipated to launch commercially in June 2026 and will mark the company's first direct product revenue milestone.

Flora Sync LF5 is based on scientific research into vaginal microbiome composition and has been studied in a clinical trial involving 100 participants. The findings have been published in a peer-reviewed journal, distinguishing it from most vaginal probiotic suppositories on the market today. The product uses Probiotical's proprietary LF5 probiotic strain and will be distributed through the DARE Health Hub.

Additionally, DARE to RECLAIM, a monthly intravaginal ring formulation combining bio-identical 17-beta-estradiol and bio-identical progesterone, is targeting availability for prescription fulfillment in 2027. This product addresses the estimated $2.5 to $4.5 billion compounded hormone therapy market and is designed to be the first monthly intravaginal delivery solution combining both bio-identical hormones.

"Daré was built on the conviction that women's health is an investment-grade category, not a niche, not a nice-to-have, not a pink ribbon in a press release," said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience.

Sabrina Martucci Johnson, President and Chief Executive Officer, Daré Bioscience

What Does This Mean for the Broader Women's Health Landscape?

The launch of these products reflects a growing recognition that women's health has historically been underfunded and understudied compared to men's health. The fact that 20 million American women lack an FDA-approved treatment for genital arousal challenges underscores how significant gaps remain in women's sexual health care.

Daré's approach of combining clinical evidence with accessible telehealth distribution represents a shift in how women's health products reach patients. By emphasizing clinician advocacy and making products available through digital channels, the company is attempting to normalize conversations around women's sexual and reproductive health while ensuring women have discreet access to treatments.

The timing of these announcements during National Women's Health Week highlights the broader movement to position women's health as a serious medical category worthy of investment and innovation. With multiple products entering the market in 2026 and 2027, Daré Bioscience is signaling that the women's health space is becoming increasingly competitive and clinically rigorous.